ライフサイエンスコーパス: clinical oncology

1 of 1,000 members of the American Society for Clinical Oncology.

2 IgE-based anticancer immunotherapy in human clinical oncology.

3 e information has become routine practice in clinical oncology.

4 ntibodies is an indispensable cornerstone of clinical oncology.

5 spectives of CTCs and ctDNA as biomarkers in clinical oncology.

6 vely few agents have found widespread use in clinical oncology.

7 r biology, and the widespread use of MTDs in clinical oncology.

8 ians, academics, and the American Society of Clinical Oncology.

9 finally, the management of allergy in daily clinical oncology.

10 relationship, tumor biology, immunology, and clinical oncology.

11 el P. Link, MD President American Society of Clinical Oncology.

12 rapy and offer a perspective on the state of clinical oncology.

13 09 Annual Meeting of the American Society of Clinical Oncology.

14 ed this article for submission to Journal of Clinical Oncology.

15 tial paradigm for differentiation therapy in clinical oncology.

16 Schilsky, MD President American Society of Clinical Oncology.

17 mple of differentiation-induction therapy in clinical oncology.

18 provement program of the American Society of Clinical Oncology.

19 is needed to ensure high-quality research in clinical oncology.

20 ents one of the major unresolved problems of clinical oncology.

21 erapy-induced alopecia is a major problem in clinical oncology.

22 t few decades and now play a central role in clinical oncology.

23 olytic viruses could enter the mainstream of clinical oncology.

24 the 2004 meeting of the American Society of Clinical Oncology.

25 lular pharmacology of anthracyclines and for clinical oncology.

26 bership directory of the American Society of Clinical Oncology.

27 esis, and its current and projected roles in clinical oncology.

28 99 Annual Meeting of the American Society of Clinical Oncology.

29 mpact that expression profiling will have on clinical oncology.

30 s who are members of the American Society of Clinical Oncology.

31 he design of immunotherapeutics relevant for clinical oncology.

32 ive multicenter comparative trials in modern clinical oncology.

33 an Cancer Society or the American Society of Clinical Oncology.

34 Cancer Journal for Clinicians and Journal of Clinical Oncology.

35 for Cancer Research and American Society of Clinical Oncology.

36 Concerns for patient safety persist in clinical oncology.

37 Cancer Research and the American Society of Clinical Oncology.

38 both Clinical Cancer Research and Journal of Clinical Oncology.

39 multidrug resistance is a central problem in clinical oncology.

40 f Controlled Trials, and American Society of Clinical Oncology abstracts were searched for cohort stu

41 ritten permission by the American Society of Clinical Oncology, American Society for Radiation Oncolo

42 Purpose A joint American Society of Clinical Oncology, American Society for Radiation Oncolo

43 d and abstracts from the American Society of Clinical Oncology, American Society of Hematology, and t

44 To update the American Society of Clinical Oncology/American Society of Hematology (ASCO/A

45 The American Society of Clinical Oncology and Cancer Care Ontario convened an ex

46 The use of PET in clinical oncology and for tissue pharmacokinetic and pha

47 n Cancer Society and the American Society of Clinical Oncology and has been published jointly by invi

48 he January 20, 2007, issue of the Journal of Clinical Oncology and in its first vignette column.

49 is an initiative of the American Society of Clinical Oncology and its Institute for Quality that add

50 The lessons from NAT are translatable to clinical oncology and may help to promote safety.

51 cular biology, health services research, and clinical oncology and the advocacy community, with a com

52 ations and efficacy, the American Society of Clinical Oncology and the American Society of Hematology

53 by invitation and consent in both Journal of Clinical Oncology and the Archives of Pathology & Labora

54 ollaboration between the American Society of Clinical Oncology and the College of American Pathologis

55 The American Society of Clinical Oncology and the College of American Pathologis

56 The American Society of Clinical Oncology and the College of American Pathologis

57 eting proceedings of the American Society of Clinical Oncology and the European Society of Medical On

58 for them periodically in both the Journal of Clinical Oncology and the Journal of Oncology Practice.

59 stracts presented at the American Society of Clinical Oncology and the San Antonio Breast Cancer Symp

60 practice guidelines, point-of-care needs in clinical oncology, and federal policy issues and implica

61 ege of Chest Physicians, American Society of Clinical Oncology, and National Comprehensive Cancer Net

62 ion for Cancer Research, American Society of Clinical Oncology, and the American Association for Canc

63 ociety for Neuroscience, American Society of Clinical Oncology, and the Radiological Society of North

64 The abstracts of the American Society of Clinical Oncology Annual Meeting between 1995 and 2014 a

65 stracts presented at the American Society of Clinical Oncology annual meetings (2004 to 2010), the Wo

66 stracts presented at the American Society of Clinical Oncology annual meetings from 2004 to 2007 were

67 of Cancer Research and American Society for Clinical Oncology annual meetings.

68 Error rates in clinical oncology are undergoing increasing scrutiny.

69 conducted as part of the American Society of Clinical Oncology (ASCO) 2001 Presidential Initiative to

70 se The panel updated the American Society of Clinical Oncology (ASCO) adjuvant therapy guideline for

71 o cancer prevention, the American Society of Clinical Oncology (ASCO) advocates a fundamental reform

72 The American Society of Clinical Oncology (ASCO) advocates for policies that ens

73 s the development of the American Society of Clinical Oncology (ASCO) and explores the role of its me

74 is an initiative of the American Society of Clinical Oncology (ASCO) and its Institute for Quality,

75 The American Society of Clinical Oncology (ASCO) and Society of Surgical Oncolog

76 recommendations from the American Society of Clinical Oncology (ASCO) and the European Organisation f

77 The American Society of Clinical Oncology (ASCO) and the European Society for Me

78 stracts presented at the American Society of Clinical Oncology (ASCO) and the European Society of Med

79 Representatives from the American Society of Clinical Oncology (ASCO) and the National Comprehensive

80 In 2008, the American Society of Clinical Oncology (ASCO) and the Oncology Nursing Societ

81 e Annual Meetings of the American Society of Clinical Oncology (ASCO) and the San Antonio Breast Canc

82 For that reason, the American Society of Clinical Oncology (ASCO) and the Society of Surgical Onc

83 Using data from American Society of Clinical Oncology (ASCO) Annual Meetings, we determined

84 g abstracts presented at American Society of Clinical Oncology (ASCO) annual meetings.

85 vention Committee of the American Society of Clinical Oncology (ASCO) believes that a proactive stanc

86 PURPOSE In 2006, the American Society of Clinical Oncology (ASCO) Board of Directors (BOD) approv

87 In December 2016, the American Society of Clinical Oncology (ASCO) Board of Directors approved the

88 In 2004, the American Society of Clinical Oncology (ASCO) Cancer Prevention Committee sur

89 The American Society of Clinical Oncology (ASCO) Cancer Research Committee desig

90 result identified by the American Society of Clinical Oncology (ASCO) Cancer Research Committee to th

91 The American Society of Clinical Oncology (ASCO) Colorectal Cancer Surveillance

92 The American Society of Clinical Oncology (ASCO) convened a panel of medical onc

93 The American Society of Clinical Oncology (ASCO) convened a panel to conduct and

94 The American Society of Clinical Oncology (ASCO) convened a subcommittee to deve

95 athology (ASCP), and the American Society of Clinical Oncology (ASCO) convened an Expert Panel to con

96 Pathology (AMP), and the American Society of Clinical Oncology (ASCO) convened an Expert Panel to dev

97 The American Society of Clinical Oncology (ASCO) developed its own test -- the M

98 The American Society of Clinical Oncology (ASCO) Endorsement Panel reviewed the

99 further reviewed by the American Society of Clinical Oncology (ASCO) Endorsement Panel.

100 The American Society of Clinical Oncology (ASCO) established a Working Group to

101 An American Society of Clinical Oncology (ASCO) Expert Panel conducted a system

102 An American Society of Clinical Oncology (ASCO) focused update updates a single

103 e recommendations of the American Society of Clinical Oncology (ASCO) for cancer-susceptibility genet

104 he outcomes specified by American Society of Clinical Oncology (ASCO) for clinical practice guideline

105 The American Society of Clinical Oncology (ASCO) Grants Program began in 1984 wi

106 To update the 2004 American Society of Clinical Oncology (ASCO) guideline on initial hormonal m

107 y recommendations of the American Society of Clinical Oncology (ASCO) guideline on the role of bone-m

108 The 2006 American Society of Clinical Oncology (ASCO) guideline recommended primary p

109 The American Society of Clinical Oncology (ASCO) guidelines program employs a sy

110 The American Society of Clinical Oncology (ASCO) has a policy and set of procedu

111 American Society of Clinical Oncology (ASCO) has a policy and set of procedu

112 The American Society of Clinical Oncology (ASCO) has a policy and set of procedu

113 The American Society of Clinical Oncology (ASCO) has a policy and set of procedu

114 The American Society of Clinical Oncology (ASCO) has a policy and set of procedu

115 The American Society of Clinical Oncology (ASCO) has a policy and set of procedu

116 The American Society of Clinical Oncology (ASCO) has a policy and set of procedu

117 The American Society of Clinical Oncology (ASCO) has a policy and set of procedu

118 ts founding in 1964, the American Society of Clinical Oncology (ASCO) has been committed to improving

119 The American Society of Clinical Oncology (ASCO) has embarked on an intensive ca

120 The American Society of Clinical Oncology (ASCO) has long affirmed that the reco

121 The American Society of Clinical Oncology (ASCO) has policies and procedures for

122 METHODS The American Society of Clinical Oncology (ASCO) Health Services Committee (HSC)

123 experts, members of the American Society of Clinical Oncology (ASCO) Health Services Committee, and

124 n outside reviewers, the American Society of Clinical Oncology (ASCO) Health Services Research Commit

125 ysicians, members of the American Society of Clinical Oncology (ASCO) Health Services Research Commit

126 The American Society of Clinical Oncology (ASCO) Health Services Research Commit

127 The American Society of Clinical Oncology (ASCO) Health Services Research Commit

128 The 2001 American Society of Clinical Oncology (ASCO) International Symposium, Breast

129 The American Society of Clinical Oncology (ASCO) is a global community of health

130 The American Society of Clinical Oncology (ASCO) is committed to improving cance

131 For the third year, the American Society of Clinical Oncology (ASCO) is publishing Clinical Cancer A

132 nd consecutive year, the American Society of Clinical Oncology (ASCO) is publishing Clinical Cancer A

133 for the first time, the American Society of Clinical Oncology (ASCO) is publishing Clinical Cancer A

134 The American Society of Clinical Oncology (ASCO) is taking the lead in this area

135 of its relevance to the American Society of Clinical Oncology (ASCO) membership, ASCO endorsed the g

136 nce of this guideline to American Society of Clinical Oncology (ASCO) membership, ASCO reviewed the g

137 ed to be relevant to the American Society of Clinical Oncology (ASCO) membership.

138 An American Society of Clinical Oncology (ASCO) panel considered the Cancer Car

139 The American Society of Clinical Oncology (ASCO) prescribed technology assessmen

140 An American Society of Clinical Oncology (ASCO) provisional clinical opinion (P

141 An American Society of Clinical Oncology (ASCO) provisional clinical opinion (P

142 An American Society of Clinical Oncology (ASCO) provisional clinical opinion (P

143 PURPOSE An American Society of Clinical Oncology (ASCO) provisional clinical opinion (P

144 An American Society of Clinical Oncology (ASCO) provisional clinical opinion (P

145 lists to update the 2012 American Society of Clinical Oncology (ASCO) provisional clinical opinion (P

146 In 1998, the American Society of Clinical Oncology (ASCO) published a special article reg

147 The American Society of Clinical Oncology (ASCO) published its first clinical pr

148 Research (AACR) and the American Society of Clinical Oncology (ASCO) recognize the potential ENDS ha

149 The American Society of Clinical Oncology (ASCO) recognizes the role of a profes

150 risk parameters from the American Society of Clinical Oncology (ASCO) recommendation did not add powe

151 0% of the members of the American Society of Clinical Oncology (ASCO) reside and practice outside US

152 American Society of Clinical Oncology (ASCO) staff reviewed the CAP/IASLC/AM

153 prescribing behavior of American Society of Clinical Oncology (ASCO) survey-reported oncologists and

154 In 1998, the American Society of Clinical Oncology (ASCO) surveyed its membership to asse

155 program developed by the American Society of Clinical Oncology (ASCO) to aid oncology practices in qu

156 irs (SPGA) Committee and American Society of Clinical Oncology (ASCO) Tobacco Cessation and Control S

157 50 of 215 members of the American Society of Clinical Oncology (ASCO) who received it.

158 The American Society of Clinical Oncology (ASCO) Working Group acknowledges that

159 ent Program (LDP) of the American Society of Clinical Oncology (ASCO), a group of participants was ch

160 he 2006 guideline of the American Society of Clinical Oncology (ASCO), a systematic review of the lit

161 cing the web page of the American Society of Clinical Oncology (ASCO), ASCO OnLine.

162 American Society of Clinical Oncology (ASCO), the leading medical profession

163 The American Society of Clinical Oncology (ASCO), the medical society representi

164 The American Society of Clinical Oncology (ASCO)-prescribed technology assessmen

165 Purpose To update the American Society of Clinical Oncology (ASCO)-Society of Surgical Oncology (S

166 the participants and the American Society of Clinical Oncology (ASCO).

167 ng patient HER2 results, American Society of Clinical Oncology (ASCO)/College of American Pathologist

168 biologic agents published in the Journal of Clinical Oncology between January 1, 2006 and June 30, 2

169 American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guidel

170 ly predicted to become a standard of care in clinical oncology, but more effective data sharing to ac

171 The American Society of Clinical Oncology Cancer Research Committee, which compr

172 romises useful applications in every part of clinical oncology care.

173 er Cancer Foundation and American Society of Clinical Oncology (Career Development Award); The Trust

174 Cancer Foundation of the American Society of Clinical Oncology, Cleveland Clinic Research Programs Co

175 In general, the American Society of Clinical Oncology clinical practice guide-lines for the

176 rable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline published

177 r new standards (eg, the American Society of Clinical Oncology/College of American Pathologists [ASCO

178 The study supports the American Society of Clinical Oncology/College of American Pathologists and C

179 the 2013 updates to the American Society of Clinical Oncology/College of American Pathologists recom

180 2013 updates to the 2007 American Society of Clinical Oncology/College of American Pathologists recom

181 proach for addressing disparities within the clinical oncology community.

182 Only 40.0% of students reported any clinical oncology component to their institution's train

183 Little is known about how clinical oncology concepts are taught to PhD students or

184 The American Society of Clinical Oncology conducted a survey of US oncologists e

185 2012 and March 2013, the American Society of Clinical Oncology conducted a survey of US oncologists e

186 d abstracts presented at American Society of Clinical Oncology conferences held between January 2000

187 , abstracts presented at American Society of Clinical Oncology conferences held between January, 2000

188 the Study of Lung Cancer/American Society of Clinical Oncology consensus workshop in New York.

189 dence-Based Care and the American Society of Clinical Oncology convened a Joint Expert Panel in Augus

190 The American Society of Clinical Oncology convened a Panel of experts in medical

191 The American Society of Clinical Oncology convened a panel of medical oncology,

192 cologic Oncology and the American Society of Clinical Oncology convened an Expert Panel and conducted

193 American Society of Clinical Oncology convened an Expert Panel of medical on

194 American Society of Clinical Oncology convened an Expert Panel of medical on

195 The American Society of Clinical Oncology convened an Expert Panel to conduct a

196 The American Society of Clinical Oncology convened an Update Committee and condu

197 The American Society of Clinical Oncology convened an Update Committee of expert

198 In clinical oncology, detecting and treating disease as ear

199 ms, assessing their institution's methods of clinical oncology education and their perspective on opt

200 d their perspective on optimal approaches to clinical oncology education.

201 ement of policy from the American Society of Clinical Oncology encourages the Secretary of the United

202 Twenty patients referred for a clinical oncology examination were scanned using a trimo

203 culty rated the value of nearly all types of clinical oncology exposure significantly lower than did

204 Using a cross-over design, 76 clinical oncology fellows/junior oncology faculty member

205 the advancement of precision medicine in the clinical oncology field.

206 e annual meetings of the American Society of Clinical Oncology (from 1999 to 2010), at the first Inte

207 a focused update of the American Society of Clinical Oncology guideline concerning use of postmastec

208 RPOSE To update the 2002 American Society of Clinical Oncology guideline on pharmacologic interventio

209 Although American Society of Clinical Oncology guidelines discourage the use of tumor

210 agreement with the 2007 American Society of Clinical Oncology guidelines on the use of biomarkers in

211 hemotoxicity, but recent American Society of Clinical Oncology guidelines recommend full dose.

212 American Society for Clinical Oncology guidelines recommend palliative chemot

213 were developed based on American Society of Clinical Oncology guidelines.

214 latelet transfusion, the American Society of Clinical Oncology has developed practice guidelines desi

215 The American Society of Clinical Oncology has established evidence-based, clinic

216 lity of TERT-based adoptive immunotherapy in clinical oncology, highlighting, for the first time, the

217 ly published by this group in the Journal of Clinical Oncology in 1998.

218 In clinical oncology, interferon-alpha remains an active an

219 clinical application of IgE-derived drugs in clinical oncology is clear if the antitumor activity of

220 The American Society of Clinical Oncology is committed to reducing the impact of

221 One of the main targets in current clinical oncology is the development of a cheap device c

222 one of the fundamental unsolved problems of clinical oncology - is driven in part by defined abnorma

223 The American Society of Clinical Oncology issued a practice guideline on use of

224 nd related phase III trials published in six clinical oncology journals in the last 3.5 years were an

225 This fundamental practice within clinical oncology limits optimization of a treatment reg

226 Cancer Research and the American Society of Clinical Oncology measured five pulmonary nodule phantom

227 became available to all American Society of Clinical Oncology member physicians in 2006 as a volunta

228 actively practicing 2005 American Society of Clinical Oncology members in the 50 United States.

229 Update Committee of the American Society of Clinical Oncology NSCLC Expert Panel based recommendatio

230 that are either already approved for use in clinical oncology or currently under preclinical or clin

231 revised opinion based on American Society of Clinical Oncology panel consensus in the context of an e

232 An American Society of Clinical Oncology Panel reviewed pertinent information f

233 An American Society of Clinical Oncology Panel, in collaboration with the Cance

234 Clinical oncology practice is interprofessional and inte

235 the CUA literature and its role in informing clinical oncology practice, research priorities, and pol

236 as not been fully incorporated into standard clinical oncology practice.

237 e the techniques' effective integration into clinical oncology practice.

238 dies, including the 2004 American Society of Clinical Oncology presentation, described in this paper

239 Evaluation Program (CTEP) and the Community Clinical Oncology Program (CCOP) grants.

240 r Institute's (NCI) Minority-Based Community Clinical Oncology Program (MBCCOP) seeks to enhance mino

241 o cancer centers and at sites in a Community Clinical Oncology Program.

242 An American Society of Clinical Oncology Provisional Clinical Opinion (PCO) off

243 ociety of Hematology and American Society of Clinical Oncology published between 2005 and 2007.

244 The American Society of Clinical Oncology Quality Oncology Practice Initiative (

245 ces participating in the American Society of Clinical Oncology Quality Oncology Practice Initiative i

246 an Society of Hematology/American Society of Clinical Oncology recommendations for use of erythropoie

247 ve revisions to the 2006 American Society of Clinical Oncology recommendations were warranted, but cl

248 As this annual American Society of Clinical Oncology report of the major cancer research ad

249 Against Cancer From the American Society of Clinical Oncology" represent the invaluable contribution

250 e assessment of cardiorespiratory fitness in clinical oncology research has increased substantially o

251 Lectures on clinical oncology research topics were the most valuable

252 This is an exciting time in clinical oncology research, because we have a plethora o

253 give recommendations for exercise testing in clinical oncology research.

254 s are being developed and adapted for use in clinical oncology research.

255 ents in our research practices in paediatric clinical oncology research.

256 y external review by the American Society of Clinical Oncology's (ASCO's) Health Services Research Co

257 The American Society of Clinical Oncology's (ASCO's) new conflict of interest po

258 is article addresses the American Society of Clinical Oncology's (ASCO's) vision for improved communi

259 The American Society of Clinical Oncology's first guideline in the 2013 Choosing

260 de (SLN) biopsy based on American Society of Clinical Oncology/Society of Surgical Oncology recommend

261 The American Society of Clinical Oncology sought to establish evidence-based, cl

262 a tool to assess trainees' knowledge of the clinical oncology subspecialty, establish consistency in

263 mission tomography has broad implications in clinical oncology, such as diagnosis, staging, and monit

264 2004 proceedings of the American Society of Clinical Oncology, the 2003 and 2004 proceedings of the

265 ted therapeutics become increasingly used in clinical oncology, the ability to quantify protein expre

266 nt was obtained from the American Society of Clinical Oncology, the American Society of Hematology, a

267 anizations including the American Society of Clinical Oncology, the European Organization for Researc

268 ed randomized trials published in Journal of Clinical Oncology, the New England Journal of Medicine,

269 Before its application in clinical oncology, this powerful technique had already a

270 ministered tyrosine kinase inhibitor used in clinical oncology to inhibit EGF signaling.

271 applied recently in an article in Journal of Clinical Oncology to measure the impact of using a genom

272 ies, including those published in Journal of Clinical Oncology , to patients seen in their own clinic

273 R pathway, cell death and the immune system, clinical oncology) to discuss the latest developments in

274 ies, including those published in Journal of Clinical Oncology, to patients seen in their own clinica

275 ies, including those published in Journal of Clinical Oncology, to patients seen in their own clinica

276 ies, including those published in Journal of Clinical Oncology, to patients seen in their own clinica

277 ies, including those published in Journal of Clinical Oncology, to patients seen in their own clinica

278 ies, including those published in Journal of Clinical Oncology, to patients seen in their own clinica

279 dies, including those published inJournal of Clinical Oncology, to patients seen in their own clinica

280 ies, including those published in Journal of Clinical Oncology, to patients seen in their own clinica

281 ies, including those published in Journal of Clinical Oncology, to patients seen in their own clinica

282 ies, including those published in Journal of Clinical Oncology, to patients seen in their own clinica

283 ies, including those published in Journal of Clinical Oncology, to patients seen in their own clinica

284 ies, including those published in Journal of Clinical Oncology, to patients seen in their own clinica

285 ies, including those published in Journal of Clinical Oncology, to patients seen in their own clinica

286 ies, including those published in Journal of Clinical Oncology, to patients seen in their own clinica

287 The study of PROs in clinical oncology trials has become well established.

288 ing children in appropriately designed adult clinical oncology trials is feasible and can be done in

289 tcomes (PROs) have become a key component of clinical oncology trials, many challenges exist regardin

290 0 inhibitors have shown promising effects in clinical oncology trials.

291 l Hsp90 inhibitor, 17-AAG, has advanced into clinical oncology trials.

292 Recommendations of the American Society of Clinical Oncology VTE Guideline Panel include (1) all ho

293 alyses performed for the American Society of Clinical Oncology VTE Guidelines Committee and the Cochr

294 y a Working Group of the American Society of Clinical Oncology were reviewed with attention to prespe

295 the guidelines from the American Society of Clinical Oncology, which suggest that all patients of ch

296 y populations; increase the diversity of the clinical oncology workforce as a requisite to improving